ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes. Therapeutic proteins are often immunogenic, inducing anaphylactic reactions and/or specific immunoglobulins.
ERYTECH Pharma Announces the Oral Presentation of Positive Phase II Clinical Trial Results in Acute Lymphoblastic Leukemia June 17, 2012 05:00 AM Eastern Daylight Time LYON, France--( BUSINESS WIRE )--The oral presentation will be held on June 17th 2012 by Prof. Dr.
ERYTECH Pharma’s Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency June 13, 2012 08:00 AM Eastern Daylight Time LYON, France--( BUSINESS WIRE )-- ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and
ERYTECH Pharma Receives € 7 Million from OSEO to Lead the TEDAC Personalized Medicine Project in Cancer Financing of € 6.95 million through grants and redeemable advances from the French public organization OSEO Leader of the collaborative project that aims to create major innovations within a
LYON, France & PHILADELPHIA--( BUSINESS WIRE )-- The first clinical trial using Graspa® on a solid tumor. A good safety profile for Graspa® in last-line therapy patients. A major step forward in its flagship product deployment in solid tumors. ERYTECH Pharma has just completed the enrollment of
Lyon (France) – October 12th, 2010 ERYtech Pharma is pleased to announce it has signed a collaborative research agreement with Genzyme Corporation to explore the feasibility of developing a novel therapeutic enzyme formulation using ERYtech’s proprietary technology.
Lyon (France), Philadelphia (USA), November 24 2009. ERYtech Pharma has been awarded ISO9001:2008 Certification. The International Organization for Standardization is the world’s leading International Standards developer. ISO 9001:2008 specifies the requirements which have been fulfilled by